Advertisement

Search Results

Advertisement



Your search for Ronald DePinho, MD,Ronald DePinho, MD matches 35 pages

Showing 1 - 35


colorectal cancer
genomics/genetics

Effect of Upregulated KDM5D Gene on Y Chromosome in Male Patients With KRAS-Mutated Colorectal Cancer

Researchers have revealed that the KDM5D gene on the Y chromosome, which is upregulated in KRAS-mutated colorectal cancer, may be responsible for increasing tumor cell invasiveness and reducing antitumor immunity in male patients, according to a recent study published by Li et al in Nature. The new ...

pancreatic cancer
immunotherapy

Triple Immunotherapy Combination Studied Preclinically for Pancreatic Cancer

Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, that successfully reprogrammed the tumor immune microenvironment and significantly improved antitumor responses in...

legislation
issues in oncology

Invest in the Unexpected: Basic Research Enterprise Needs Adequate Funding to Foster Treatment Innovation

The National Institutes of Health (NIH) now stands as the largest single public funder of biomedical research in the world.1 The FY2022 Consolidated Appropriations Act (H.R. 2471), signed into law in March, increases biomedical research funding by nearly 5%, and it provides a total of $45 billion...

colorectal cancer
head and neck cancer
pancreatic cancer

Early Research Shows Potential New Targets in Treating Glioblastoma, Colorectal Cancer, and Pancreatic Ductal Adenocarcinoma

Glioblastoma multiforme, colorectal cancer, and pancreatic ductal adenocarcinoma represent some of the most difficult-to-treat cancers and collectively cause more than 114,000 deaths each year in the United States. A trio of recently published basic research studies in these cancers have found...

Peter W.T. Pisters, MD, MHCM, Named Sole Finalist in Search for President, MD Anderson

The University of Texas System Board of Regents has selected Peter W.T. Pisters, MD, MHCM, as sole finalist for the position of president at The University of Texas MD Anderson Cancer Center in Houston. The regents voted unanimously to select Dr. Pisters at a special board meeting on Friday,...

Peter W.T. Pisters, MD, MHCM, Named Sole Finalist in Search for President, MD Anderson

The University of Texas System Board of Regents has selected Peter W.T. Pisters, MD, MHCM, as sole finalist for the position of President at The University of Texas MD Anderson Cancer Center in Houston.  The regents voted unanimously to select Dr. Pisters at a special board meeting on Friday,...

health-care policy
legislation

Making American Research Great Again

In the past 10 years, we have made remarkable advances in how we fight cancer. One of the most powerful new tools in our arsenal is cancer immunotherapy, which reawakens our own immune system to produce stunning results for many suffering from advanced cancer. Immunotherapy saved President Jimmy...

Ronald A. DePinho, MD, to Resign as President of MD Anderson

Ronald A. DePinho, MD, President of The University of Texas MD Anderson Cancer Center, has submitted a letter to Chancellor William H. McRaven of the University of Texas System tendering his resignation. Chancellor McRaven has asked Dr. DePinho to stay on through the end of the Texas Legislative...

Leader in Cancer Care and Prevention, Charles A. LeMaistre, MD, Dies

In 1978, Charles A. “Mickey” LeMaistre, MD, was named President of The University of Texas MD Anderson Cancer Center. During his 18-year tenure, MD Anderson became a world leader in outpatient care for cancer patients and the nation’s largest ambulatory treatment and surgery programs in cancers....

prostate cancer

Researchers Identify ‘Synthetic Essentiality’ as Novel Approach for Locating Cancer Therapy Targets

A new method has been found for identifying therapeutic targets in cancers lacking specific key tumor suppressor genes. The process, which located a genetic site for the most common form of prostate cancer, has potential for developing precision therapy for other cancers, such as breast, brain, and ...

pancreatic cancer
gastrointestinal cancer
colorectal cancer

‘Collateral Lethality’ May Offer New Therapeutic Approach to Cancers of the Pancreas, Stomach, and Colon

Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for the development of therapies for several cancers. Scientists at The University of Texas MD...

solid tumors

‘Collateral Lethality’ May Offer New Therapeutic Approach for Cancers of the Pancreas, Stomach, and Colon

Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for development of therapies for several cancers. Scientists at The University of Texas MD ...

health-care policy

Oncology Organizations Applaud Passage of the 21st Century Cures Act

On Tuesday, December 13, President Obama signed into law the 21st Century Cures Act, landmark legislation designed to improve and accelerate the pace of biomedical research in the United States. ASCO Chief Executive Officer Clifford Hudis, MD, FACP, FASCO, attended the White House signing ceremony ...

Richard Gorlick, MD, Joins MD Anderson to Lead Pediatrics

Richard Gorlick, MD, an expert in pediatric oncology and hematology, has joined The University of Texas MD Anderson Children’s Cancer Hospital as the Division Head and Department Chair of Pediatrics. A pediatric cancer survivor himself, Dr. Gorlick committed his life’s work to helping young...

Seven MD Anderson Faculty Elected Fellows of the American Association for the Advancement of Science

In recognition of wide-ranging contributions to the fields of cancer prevention; patient care; and basic, translational, and clinical research, seven faculty members from The University of Texas MD Anderson Cancer Center have been named Fellows of the American Association for the Advancement of...

MD Anderson Cancer Center Marks 75 Years of Research to End Cancer

In November, The University of Texas MD Anderson Cancer Center celebrated its 75th anniversary with a week-long series of events that raised nearly $15 million to support its efforts in patient care and in the investigation and treatment of cancer. Housed on 16 million square feet in the city of...

issues in oncology
cost of care

Reducing Drug Costs by Increasing Science-Driven Drug Discovery

For several years now, the American health-care system has been undergoing a transformation. Innovative ideas are being explored, new systems continue to be created, and millions of lives have been impacted. As health-care providers and research engines, academic institutions have an opportunity...

health-care policy
issues in oncology

Supporting Policy to Reduce Tobacco-Related Deaths

One billion lives. That is the estimated human death toll of tobacco use in the 21st century.1 Tobacco use is the leading cause of preventable death worldwide—20% of all deaths and 30% of cancer deaths in the United States are linked to tobacco use.2,3 Impacting this preventable public health...

MD Anderson Receives $10.6 Million From CPRIT for Lung Cancer Research

The University of Texas MD Anderson Cancer Center will receive $10.6 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT) for two collaborative studies targeting crucial issues in lung cancer. The two multi-investigator research awards, designed to support teams of...

issues in oncology

Dethroning the Emperor of All Maladies

Deep knowledge of immunology, cancer biology, and disruptive technology in computational science and molecular profiling has positioned us to dethrone the emperor of all maladies. The cancer research community is prepared to fulfill President Barack Obama’s call for a national cancer moonshot aimed ...

issues in oncology

MD Anderson Cancer Center’s New President Has a Bold Vision

On September 1, 2011, Ronald A. DePinho, MD, became only the fourth President in the 70-year history of The University of Texas MD Anderson Cancer Center in Houston. Dr. DePinho spent the previous 14 years as head of Dana-Farber’s Belfer Institute for Applied Cancer Science. In a recent interview...

Research Leader Helen Piwnica-Worms, PhD, Appointed Vice Provost, Science, at UT MD Anderson Cancer Center

Helen Piwnica-Worms, PhD, a leader and scientist whose success in cancer research spans the spectrum from basic science discovery through arduous preclinical follow-up and delivery of potential new drugs to clinical trial, will lead science research at The University of Texas MD Anderson Cancer...

Dual Awards Pay Tribute to Gender Equity Trailblazers

The University of Texas MD Anderson Cancer Center in Houston recently recognized two leading advocates for women in medicine and research. Karen Antman, MD, Provost of the Boston University Medical Campus and Dean of its School of Medicine since 2005, was the recipient of the 2013 Margaret L....

MD Anderson Honors Two Champions for Women in Medicine and Research

Two champions of gender equality in medicine and research were recently honored by The University of Texas MD Anderson Cancer Center. Laurie Glimcher, MD, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and Provost for Medical Affairs of Cornell University since 2012, received...

Setting a ‘Moon Shots’ Goal to Drastically Reduce Cancer Mortality Over the Next Decade

In 2012, just 1 year after taking the reins as President of The University of Texas MD Anderson Cancer Center, Ronald A. DePinho, MD, announced his plans to launch the Moon Shots Program, the most ambitious endeavor undertaken by the cancer center to dramatically accelerate the pace of reducing...

James P. Allison, PhD, Receives 2014 Canada Gairdner International Award

The Gairdner Foundation of Canada has named James P. Allison, PhD, for one of its 2014 Canada Gairdner International Awards. Dr. Allison is Chair and Professor of Immunology at The University of Texas MD Anderson Cancer Center in Houston. The honor, announced recently by the Gairdner Foundation,...

Advancing Immune Checkpoint Targeting in Cancer Treatment

James P. Allison, PhD, Professor and Chair of the Department of Immunology, Executive Director of the Moon Shots Immunotherapy Platform, and Deputy Directory of the David H. Koch Center for Applied Research of Genitourinary Cancers at The University of Texas MD Anderson Cancer Center, Houston, is...

American Association for Cancer Research Inducts 2015 Class of Fellows of the AACR Academy

The American Association for Cancer Research (AACR) has announced 11 new fellows of the AACR Academy. The AACR Academy is an entity that recognizes individuals who have made exceptional contributions to cancer research and/or cancer-related biomedical science. Only individuals whose work has had a...

James Allison, PhD, Receives 2015 AACR Pezcoller Award

James Allison, PhD, was named a recipient of the 2015 Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Cancer Research at the 2015 AACR Annual Meeting. Dr. Allison, Chair of Immunology at The University of Texas MD Anderson Cancer Center, was acknowledged ...

leukemia

A Lasting Legacy

When Emil J Freireich, MD, retires from the University of Texas MD Anderson Cancer Center on September 1, he will have spent 50 years at the institution and a total of 60 years in the pursuit of curing childhood leukemia as well as other cancers and in the educational development of young...

James P. Allison, PhD, Wins Clinical Medical Research Lasker-DeBakey Award

James P. Allison, PhD, Chair of Immunology at The University of Texas MD Anderson Cancer Center, has been named the 2015 winner of the Lasker-DeBakey Clinical Medical Research Award from the Albert and Mary Lasker Foundation. The Lasker awards, in their 70th year, honor major achievements in basic...

issues in oncology

Our Children’s Future Is Our Responsibility

Cancer prevention is a child-care issue. With many of cancer’s instigators planting their seeds during childhood, we—as a profession and as a nation—must seize this important window of opportunity to protect the health and well-being of future generations. Current estimates suggest that up to...

NYU Langone Appoints Alec Kimmelman, MD, PhD, as Chair of Radiation Oncology

Renowned clinician-scientist Alec Kimmelman, MD, PhD, has been named Chair of the Department of Radiation Oncology at NYU Langone Medical Center. His appointment is effective February 1, 2016. Dr. Kimmelman joins the Laura and Isaac Perlmutter Cancer Center at NYU Langone following a distinguished...

MD Anderson Receives $22.2 Million in CPRIT Research Funding

The University of Texas MD Anderson Cancer Center was awarded more than $22 million in research grants from the Cancer Prevention and Research Institute of Texas (CPRIT). Thirty-six percent of funds awarded for Individual Investigator Awards went to MD Anderson faculty, as well as nearly 40% of...

gynecologic cancers
issues in oncology

A Shot to End Cancer: HPV Vaccination

As health-care providers, we have an obligation and a responsibility not only to care for our patients, but also to educate them—and the general public—about their cancer risk and ways to reduce or prevent it. We are living in the golden era of cancer prevention and treatment, made possible by...

Advertisement

Advertisement




Advertisement